Skip to main content
. 2020 Apr 22;9(12):4148–4159. doi: 10.1002/cam4.3056

Figure 5.

Figure 5

Efficacy of chronoIFLO according to irinotecan timing in the morning, in the afternoon or at night in each sex. Progression‐free survival curves in (A) male patients and (B) female patients. Overall survival curves according to irinotecan timing in (C) male patients and (D) female patients (see Table S3 for statistical comparisons)